Biotech News
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
SELLAS Life Sciences Group, Inc. (SLS)SELLAS Life Sciences Group, Inc.2026-06-25 13:46 ESTClinical readout
SLS (SLS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.
The source domain is sls.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.
The original release is available below in a new tab so readers can continue into the full source when needed.